To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Alendronate
Alendronate (Fosamax, Merck) is a bisphosphonate drug used for osteoporosis and several other bone diseases. It is marketed alone as well as in combination with vitamin D (2,800 U and 5600 U, under the name Fosamax+D). Merck's U.S. patent on alendronate is set to expire in 2008 and Merck has lost a series of appeals to block a generic version of the drug from being certified by the U.S. Food and Drug Administration. Additional recommended knowledge
PharmacokineticsAs with all potent bisphosphonates, the systemic bioavailability after oral dosing is low, averaging only 0.6 - 0.7 % in women and in men under fasting conditions. Intake together with meals and beverages other than water further reduces the bioavailability. The absorbed drug rapidly partitions, with approximately 50% binding to the exposed bone surface; the remainder is excreted unchanged by the kidneys. Unlike most drugs, the strong negative charge on the two phosphate moieties limits oral bioavailability, and in turn, the exposure to tissues other than bone is very low. After absorption in the bone, alendronate has an estimated terminal half-life of 10 years.[citation needed] PharmacologyAlendronate inhibits osteoclast-mediated bone-resorption. Like all bisphosphonates it is chemically related to inorganic pyrophosphate, the endogenous regulator of bone turnover. Whereas pyrophosphate and the first bisphosphonate, etidronate, are capable of inhibiting both osteoclastic bone resorption as well as the mineralization of the bone newly formed by osteoblasts, alendronate and the other potent N-containing bisphosphonates such as risedronate and ibandronate and zoledronate specifically inhibit bone resorption without any effect on mineralization at pharmacalogically achievable doses. Its inhibition of bone-resorption is dose-dependent and approximately 1,000 times stronger than the equimolar effect of etidronate. Under therapy normal bone tissue develops, and alendronate is deposited in the bone-matrix in pharmacologically inactive form. For optimal action enough calcium and vitamin D are needed in the body in order to promote normal bone development. Hypocalcemia should therefore be corrected before starting therapy. Clinical DataTreatment of post-menopausal women with Fosamax has demonstrated normalization of the rate of bone turnover, significant increase in BMD (bone mineral density) of the spine, hip, wrist and total body, and significant reductions in the risk of vertebral (spine) fractures, wrist fractures, hip fractures, and all non-vertebral fractures. In the women with the highest risk of fracture (by virtue of pre-existing vertebral fractures) in the Fracture Intervention Trial, treatment with Fosamax 5 mg/day for two years followed by 10 mg/day for the third year (plus calcium and vitamin D) resulted in approximately 50% reductions in fractures of the spine, hip and wrist compared to the control group taking placebos plus calcium and vitamin D. Uses
Contraindications and precautions
Side-effects
Interactions
Dosage
The drug is to be taken only upon rising for the day with three swallows of water, not to exceed 6-8 oz. Stand, walk or sit and remain fasting for 30-45 minutes afterwards, then eat breakfast. Lying down or reclining prior to eating breakfast may cause gastroesophageal reflux and esophageal irritation. At least 30 minutes should be waited before meals or other beverages than water are taken in. Dosage forms
LitigationBy 2000 the FDA had received 139 spontaneous reports through the MedWatch system of osteonecrosis of the jaw (ONJ) in cancer patients treated with intravenous (IV) bisphopshonates, either IV pamidronate (Aredia) or IV zolendronate (Zometa). Spontaneous reports cannot prove causality, as patients with cancer (and some without cancer) develop spontaneous ONJ, and hundreds of thousands of cancer patients had been treated with these IV bisphosphonates. Despite the fact that many millions of patients had been treated with oral bisphosphonates such as Fosamax and Actonel, not one of the 139 MedWatch reports involved a patient treated only with an oral bisphosphonate. In order to dtermine if the IV bisphosphonates were causally related to ONJ, the FDA asked Novartis, the manufacturer of both drugs, to screen their completed Phase 3 program databases with a collection of MEDdra terms designed to catch all possible cases of ONJ (most of the terms were not specific for ONJ, but coded for "jaw pain", "jaw infection", etc.). Novartis returned to the ODAC (Oncology Drugs Advisory Committee) meeting in 2004, and presented data demonstrating a number of "hits" to any of these terms as well as 6 cases of actual ONJ; all 6 of the ONJ cases occurred in patients treated with pamidronate (Aredia) or zolendronate (Zometa) vs no cases in the placebo group. This proves causality, and FDA required both drugs to include a warning in their label that use of the drugs increases the risk of ONJ. At the 2004 ODAC meeting the number of spontaneous reports had increased since 2000, and although almost all of the reports remained in cancer patients treated with one of the IV bisphosphonates 13 of the reports were in patients taking oral alendronate or risedronate, most of which were reported on September 24, 2004 in the Journal of Oral and Maxillofacial Surgury. Although this small number of reports (several of which do not appear to represent true ONJ) do not remotely indicate causality, given the millions of patients who have been treated with alendronate and risedronate, in order to be cautious the Food and Drug Administration (FDA) asked the manufacturer of the oral bisphosphonates (Merck for Fosamax, Procter & Gamble and Aventis for Actonel, and Roche and GSK for Boniva) to issue a warning to health care professionals of the potential that alendronate, risedronate and ibandronate and their brand name equivalents, Fosamax, Actonel and Boniva might increase the risk of ONJ. When the alendronate Fracture Intervention Trial database (containing almost 25,000 patient-years, larger than the pamidronate and zolendronate databases) was screeened with the same MEDdra terms, not a single case of ONJ was identified. A total of only 10 patients had a "hit" to any of the terms (none of which were ONJ), of whom 4 were in the Fosamax group and six were in the placebo group. Three of the 10 patients had adverse events that involved the jaw, none of which were ONJ, and all three patients were in the placebo group. Despite the fact that no data links the oral bisphosphonates (which are used at much lower doses than the IV bisphosphonates) causally to ONJ, product liability attorneys immediately filed suit maintaining this condition is far more widespread than initially indicated, and maintaining that their claimants' ONJ is a direct result of the use of alendronate. Merck has stated the "underlying cause" of osteonecrosis of the jaw is "uncertain", though it might be triggered by a traumatic event like tooth extraction or oral surgery. As of May 13, 2007, hundreds of cases had been filed against Merck alleging Fosamax-induced ONJ. Most of the cases are consolidated for pretrial purposes in the United States District Court for the Southern District of New York (MDL 1789). The first case is set to be tried in late 2008 before the Honorable John F. Keenan, District Judge for the Southern District of New York. Bis-phossy JawThe term given by scientists to the link between bisphosphonates and jaw necrosis is 'bis-phossy jaw.' This is derived from the 19th-century term phossy jaw, given its name after workers in match factories working with white phosphorus developed osteonecrosis of the jaw.
Categories: Bisphosphonates | Merck |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Alendronate". A list of authors is available in Wikipedia. |